The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Denosumab Does Not Stimulate Early Bone Formation

Denosumab Does Not Stimulate Early Bone Formation

February 29, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company.

You Might Also Like
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • New Data May Explain the Role of Sclerostin in Bone Formation

Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab administration, suggesting the possibility that it could increase early bone formation, researchers say.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. David W. Dempster from Columbia University, New York, and colleagues characterized denosumab-induced changes in iPTH levels in conjunction with bone histomorphometric indices and bone turnover markers and compared these effects with those induced by the anabolic agent teriparatide (an analog of PTH).

Their open-label, randomized study included 69 postmenopausal women with osteoporosis, and the primary endpoint was the change from baseline to three months in mineralizing surface/bone surface (MS/BS) in the cancellous envelope of transiliac bone biopsies. MS/BS, they say, readily distinguishes between anabolic and antiresorptive mechanisms of action.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The two treatment groups were similar, except that the denosumab group was significantly older than the teriparatide group (65.2 vs. 61.6 years).

After the first month of treatment, iPTH levels had increased a mean 89.6% in the denosumab group and dropped 27.1% in the teriparatide group, the researchers report in an article online Feb. 9 in The Journal of Clinical Epidemiology & Metabolism.

iPTH levels declined after the first month in the denosumab group, but remained 31.9% higher than baseline at six months. In the teriparatide group, iPTH levels remained 35.3% lower than baseline at six months.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Bone turnover markers P1NP and CTX were significantly reduced after denosumab treatment and significantly increased after teriparatide treatment.

At three months, MS/BS had increased by a median 12.4 percentage points with teriparatide and had decreased by a median 2.5 percentage points with denosumab, a clear indication of increased new bone formation with teriparatide and decreased new bone formation with denosumab.

Median mineral apposition rate (MAR) did not change significantly with teriparatide therapy but decreased significantly with denosumab therapy.

Treatment-emergent adverse effects were more common with teriparatide (81.8%) than with denosumab (63.9%).

“The increase in PTH that we observed in our study is not unique to denosumab and may be an attribute of the antiresorptive drug class because iPTH also increases in response to alendronate and zoledronic acid treatment,” the researchers note.

“Our data suggest that the sustained and substantial increases in bone mineral density (BMD) seen with denosumab treatment are not explained by indirect anabolic action induced by increases in endogenous PTH and must be caused by other mechanism(s),” the authors conclude.

Eli Lilly and Company, which manufactures teriparatide, sponsored the trial, employed five of the 15 authors, and had various relationships with all but one of the others.

Dr. Dempster did not respond to a request for comments.

Pages: 1 2 | Multi-Page

Filed Under: Conditions Tagged With: bone, bone formation, denosumab, Osteoporosis, postmenopause, Women

You Might Also Like:
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • New Data May Explain the Role of Sclerostin in Bone Formation
  • A Parathyroid Hormone Both Builds & Destroys Bone

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.